News

The Fondazione Telethon agent, etuvetidigene autotemcel, significantly reduced severe infections and bleeding events in clinical studies.

Deevyashali Parekh, MBBS, an internal medicine resident at SUNY Upstate Medical University Hospital, discussed findings from a patient population traditionally excluded from clinical trials for CAR-T.

The chairman of the Division of Pediatric Hematology & Oncology and BMT at Cleveland Clinic Children's discussed results from the phase 1/2 RUBY trial he presented at ASH 2025.

ImmunoLogic cohost Janna Minehart, MD, discussed a few exciting immunotherapy sessions she attended at ASH's Annual Meeting.

The internal medicine resident at SUNY Upstate Medical University Hospital discussed findings from a patient population traditionally excluded from clinical trials for CAR-T.

Crawford Strunk, MD, an associate staff member at the Cleveland Clinic, discussed the institution's experience with integrating use of exa-cel and lovo-cel.

The clinical fellow in hematology/oncology at the University of Pennsylvania discussed several sessions she's excited about at the ASH Annual Meeting.

The associate staff member at the Cleveland Clinic discussed the institution's experience with integrating use of exa-cel and lovo-cel.

Crawford Strunk, MD, an associate staff member at the Cleveland Clinic, discussed a study he presented at ASH’s 2025 Annual Meeting.

AZD0120, a dual-targeted CAR T-cell therapy, shows high efficacy in treating relapsed multiple myeloma, achieving a 96% response rate.

Review top news and interview highlights from the week ending December 5, 2025.

Colleen Caleshu, MS, CGC, the senior director of research and real world data at Genome Medical, discussed a session she chaired at the NSGC Annual Conference.

The agency's decision was based on results from an r/r MZL cohort in the phase 2 TRANSCEND FL clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed lessons that should guide the next generation of developers and regulators entering the field.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about how our understanding of advanced therapeutics is still evolving.

In episode 7 of ImmunoLogic, Anusha Kalbasi, MD, discussed his research on the use of IL-9 to enhance CAR-T efficacy.

The research director at the Clinic for Special Children discussed how screening at-risk patients can speed up diagnosis and treatment of spinal muscular atrophy.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending November 28, 2025.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about streamlining collaboration to speed up advancement of new therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA also added a new Warnings & Precaution for heightened susceptibility to serious infections caused by immunosuppression.

According to Novartis, it is the first gene replacement therapy to have been approved “for this broad population.”

The NSGC president-elect spoke on the evolving role of genetic counselors, emphasizing personalized care, gene therapy advancements, and the need for multidisciplinary integration in healthcare.

Review top news and interview highlights from the week ending November 21, 2025.

The genetic counselor in the Department of Ophthalmology at the University of Pittsburgh Medical Center discussed the growing role of genetic counselors in guiding patients undergoing gene therapy.